Online citations, reference lists, and bibliographies.
← Back to Search

S3‐Leitlinie Zur Therapie Der Psoriasis Vulgaris

A. Nast, I. Kopp, M. Augustin, K. Banditt, W. Boehncke, M. Follmann, M. Friedrich, M. Huber, C. Kahl, J. Klaus, J. Koza, I. Kreiselmaier, Johannes Mohr, U. Mrowietz, H. Ockenfels, H. Orzechowski, J. Prinz, K. Reich, T. Rosenbach, S. Rosumeck, M. Schlaeger, G. Schmid‐Ott, M. Sebastian, V. Streit, T. Weberschock, B. Rzany
Published 2006 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Die erkrankten Patienten leiden an einer deutlichen Einschrankung der Lebensqualitat durch ihre Erkrankung an der Psoriasis vulgaris. Untersuchungen zur Einschrankung der Lebensqualitat bei den Patienten haben ergeben, dass durch die Erkrankung in Abhangigkeit vom Schweregrad eine erhebliche Belastung in Form einer Behinderung bzw. psychosozialen Stigmatisierung bestehen kann [2]. In Patientenbefragungen wurde eine Beeintrachtigung der Lebensqualitat festgestellt, die u.a. vergleichbar ist mit der eines Typ-2-Diabetes oder einer chronischen Lungenerkrankung [3].
This paper references
10.1016/S0190-9622(99)80057-7
Patients with psoriasis and their compliance with medication.
H. Richards (1999)
[Acute toxic polyneuropathy following short-time hydroxyquinoline administration].
W. Müller (1979)
10.1038/357692A0
FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin
S. J. O'Keefe (1992)
10.1111/1523-1747.EP12512282
The effect of anthralin and its derivatives on epidermal cell kinetics.
L. B. Fisher (1975)
10.1046/J.1523-1747.2001.01159.X
Inhibition of dendritic cell differentiation by fumaric acid esters.
K. Zhu (2001)
10.1159/000029819
Dithranol Embedded in Crystalline Monoglycerides Combined with Phototherapy (UVB): A New Approach in the Treatment of Psoriasis
M. Gerritsen (1998)
10.1111/j.1365-2133.2004.05986.x
Efficacy of once‐daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris
K. Kragballe (2004)
10.1159/000065971
Calcipotriol Plus Short-Contact Dithranol: A Novel Topical Combination Therapy for Chronic Plaque Psoriasis
A. Monastirli (2002)
Benefits and adverse drug experiences during long-term methotrexate treatment of 248 psoriatics.
A. Nyfors (1978)
10.1056/NEJMOA021359
Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis.
V. M. Heydendael (2003)
10.1001/ARCHDERM.1985.01660100077019
Isotretinoin vs etretinate therapy in generalized pustular and chronic psoriasis.
R. Moy (1985)
10.1001/ARCHDERM.1989.01670210056007
The role of liver biopsies in psoriatic patients receiving long-term methotrexate treatment. Improvement in liver abnormalities after cessation of treatment.
M. Newman (1989)
10.1067/MJD.2003.169
Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas.
A. Freeman (2003)
Methotrexate induced liver cirrhosis. Studies including serial liver biopsies during continued treatment
H Zachariae (1980)
Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison of 8-methoxypsoralen and 5-methoxypsoralen.
M. Berg (1994)
10.1067/MJD.2003.103
Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks.
G. Weinstein (2003)
10.1046/j.1529-8019.2003.01622.x
Balneotherapy in dermatology
H. Matz (2003)
10.1111/j.1468-3083.1998.tb00948.x
Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis
J. Austad (1998)
10.1001/ARCHDERM.1983.01650270025011
Topical steroids and UV radiation in psoriasis.
J. Petrozzi (1983)
A new treatment of ichthyosis and other hyperkeratotic conditions.
G. Swanbeck (1968)
10.1159/000017515
Depth Psychology-Founded Psychotherapy of Psoriatic Patients – Treatment of a Patient with Chronic Recidivating Psoriasis vulgaris
G. Schmid-Ott (2000)
10.1111/J.1699-0463.1977.TB03882.X
Liver biopsies from psoriatics related to methotrexate therapy. 3. Findings in post-methotrexate liver biopsies from 160 psoriatics.
A. Nyfors (1977)
10.1002/ART.20335
Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression.
P. Mease (2004)
10.1111/1523-1747.EP12499901
Anthralin decreases keratinocyte TGF-alpha expression and EGF-receptor binding in vitro.
A. Gottlieb (1992)
10.1046/j.1365-2133.1999.140S54018.x
Combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis
Gollnick (1999)
10.1159/000080854
Efficacy of Treatment with Calcipotriol/Betamethasone Dipropionate Followed by Calcipotriol Alone Compared with Tacalcitol for the Treatment of Psoriasis vulgaris: A Randomised, Double-Blind Trial
J. Ortonne (2004)
10.1046/J.1087-0024.2003.09102.X
Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction.
R. Stern (2004)
10.1016/S0190-9622(94)70138-5
A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study.
R. M. Grossman (1994)
10.1111/j.1600-0536.1996.tb02199.x
Ultrasound description and quantification of irritant reactions induced by dithranol at different concentrations
M. Schiavi (1996)
10.1002/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7
Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study.
A. V. van Ede (2001)
A randomized trial of etanercept as monotherapy for psoriasis
T. Rindflesch (2005)
Fachinformation, Wyeth; aktuelle Version
10.1080/00015550252948194
A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris.
W. S. Douglas (2002)
[Fumaric acid therapy in psoriasis; a double-blind, placebo-controlled study].
W. M. Nugteren-Huying (1990)
10.1111/j.1365-2133.1995.tb02754.x
Sequential liver biopsies during long‐term methotrexate treatment for psoriasis: a reappraisal
M. Boffa (1995)
10.1111/j.1365-2133.1994.tb02935.x
Efficacy and safety of oral cyclosporin A (CyA; Sandimmun®) for long‐term treatment of chronic severe plaque psoriasis
C. Laburte (1994)
10.1016/S0190-9622(98)70323-8
Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement.
M. Lebwohl (1998)
10.1159/000018309
Calcipotriol Cream Combined with Twice Weekly Broad-Band UVB Phototherapy: A Safe, Effective and UVB-Sparing Antipsoriatric Combination Treatment
C. Ramsay (2000)
10.1046/j.1365-2133.1996.d01-1035.x
Psoriasis in the community: prevalence, severity and patients' beliefs and attitudes towards the disease
G. J. Nevitt (1996)
A comparison of twice-weekly MPD-PUVA regimens for the treatment psoriasis
D A Buckley (1995)
10.1111/1523-1747.EP12461062
Comparison of hypothalamus-pituitary-adrenal axis suppression from superpotent topical steroids by standard endocrine function testing and gas chromatographic mass spectrometry.
W. Weston (1988)
10.1046/j.1365-4362.2001.01167.x
Investigator‐masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis
J. Koo (2001)
10.1159/000246849
Safety and effectiveness of an aggressive and individualized bath-PUVA regimen in the treatment of psoriasis.
P. Calzavara-Pinton (1994)
10.1016/S0190-9622(00)90214-7
Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis.
A. Gottlieb (2000)
10.1001/ARCHDERM.1980.01640280049016
Methotrexate hepatotoxicity in psoriasis. Consideration of liver biopsies at regular intervals.
J. Robinson (1980)
A randomized double-blind comparison of PUVAetretinate and PUVA-placebo in the treatment of chronic plaque psoriasis
S Parker
10.1046/j.1365-2230.2001.00870.x
Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis
M. Ameen (2001)
A randomized comparison of three conventional modes of treatment of psoriasis of the scalp.
Ross Sd (1981)
10.1111/j.1365-2133.2004.06070.x
Biological therapies in the systemic management of psoriasis: International Consensus Conference
W. Sterry (2004)
10.1056/NEJM197412052912301
Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light.
J. Parrish (1974)
10.1159/000248398
Benefit of progressively increasing doses during the initial treatment with acitretin in psoriasis.
P. Berbis (1989)
10.1002/j.1552-4604.1995.tb04131.x
Efficacy and Pharmacokinetics of Two Formulations of Cyclosporine A in Patients with Psoriasis
Cheryl A. Elder (1995)
10.1016/S0190-9622(89)70085-2
Are topical corticosteroids useful in phototherapy for psoriasis?
J. S. Dover (1989)
10.1111/J.1600-0536.1994.TB01965.X
Intolerance and contact allergy to tar and dithranol in psoriasis
A. Burden (1994)
10.1016/S0140-6736(00)04954-0
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
U. Chaudhari (2001)
10.1097/00007611-197811000-00009
Treatment of Psoriasis With 8‐Methoxypsoralen and Sunlight
D. Robertson (1978)
10.1159/000249273
Irritant potential of dithranol.
U. F. Haustein (1986)
10.1001/ARCHDERM.138.9.1221
The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review.
J. de Korte (2002)
Severe forms of psoriasis: clinical and experimental studies
A.L.A. Kuijpers (1998)
Management of guttate and generalized psoriasis vulgaris: prospective randomized study.
N. G. Caca-Biljanovska (2002)
10.1111/j.1365-2133.1975.tb06498.x
A prospective study of the effects of weekly oral methotrexate on liver biopsy
A. Warin (1975)
10.1111/j.1468-3083.2004.01054.x
Psoriasis of the glans penis in a child successfully treated with ElidelR (pimecrolimus) cream
B. Amichai (2004)
10.1016/J.JAAD.2004.06.010
Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study.
Carin H. Gribetz (2004)
A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study.
K. Kragballe (1989)
10.1016/0167-5699(93)90061-O
The mechanisms of action of cyclosporin A in the treatment of psoriasis.
R. Wong (1993)
Intralesional cyclosporin in psoriasis.
A. Powles (1989)
Beeinflussung der Psoriasis durch Cyclosporin A
W Müller (1979)
10.1016/S0190-9622(99)70112-X
Psoriasis causes as much disability as other major medical diseases.
S. Rapp (1999)
10.1016/S0149-2918(00)83065-9
A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis.
L. Guenther (2000)
10.1111/j.1365-2133.1987.tb04920.x
Dithranol mediates pro‐oxidative inhibition of polymorphonuclear leukocyte migration and lymphocyte proliferation
R. Anderson (1987)
10.1016/S0190-9622(89)70071-2
Systemic therapy with fumaric acid derivates: new possibilities in the treatment of psoriasis.
C. Nieboer (1989)
10.1111/j.1365-2133.1990.tb01481.x
Cyclosporin A in combination with photochemotherapy (PUVA) in the treatment of psoriasis
P. Petzelbauer (1990)
10.1016/S0002-9343(05)80060-9
Methotrexate and histologic hepatic abnormalities: a meta-analysis.
Q. Whiting-O'Keefe (1991)
Christophers E. Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study
D Thaci (2002)
10.1136/oem.29.2.188
Scrotal cancer in the north-west of England, 1962-68
W. R. Lee (1972)
10.1016/S0190-9622(89)70154-7
Effectiveness of cyclosporine treatment in severe psoriasis: a clinical and immunologic study.
A. Finzi (1989)
10.1002/EJI.1830260916
Selective stimulation of T helper 2 cytokine responses by the anti‐psoriasis agent monomethylfumarate
R. D. de Jong (1996)
10.1034/j.1600-0781.2000.160502.x
Comparison of phototherapy two times and four times a week with low doses of narrow‐band ultraviolet B in Asian patients with psoriasis
V. Leenutaphong (2000)
10.1159/000247286
Cyclosporin versus etretinate: Italian multicenter comparative trial in severe plaque-form psoriasis. Italian Multicenter Study Group on Cyclosporin in Psoriasis.
A. Finzi (1993)
10.1016/S0140-6736(01)06179-7
Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study
I. Marcil (2001)
10.1111/j.1365-2133.1992.tb00460.x
Bath‐water compared with oral delivery of 8‐methoxypsoralen PUVA therapy for chronic plaque psoriasis
P. C. Llins (1992)
10.2340/00015555756569
Remission of ordinary psoriasis following a short clearance course of cyclosporin.
N. Levell (1995)
10.1007/s00105-005-0906-9
Psychosoziale Folgen der Psoriasis—eine empirische Studie über die Krankheitslast bei 3753 Betroffenen
G. Schmid‐Ott (2005)
Safety and efficacy of over 7 years of etanercept therapy in a global population of patients with rheumatoid arthritis
M Lebwohl (2005)
10.1067/MJD.2002.120454
Efficacy of the 308-nm excimer laser for treatment of psoriasis: results of a multicenter study.
S. Feldman (2002)
10.1111/j.1365-2230.1986.tb00457.x
Salicyclic acid gel for scalp psoriasis
S. Going (1986)
10.1001/ARCHDERM.1979.04010070016013
Tar gel-phototherapy for psoriasis. Combined therapy with suberythemogenic doses of fluorescent sunlamp ultraviolet radiation.
P. Frost (1979)
10.1016/S0190-9622(08)80228-9
Fumaric acid therapy in psoriasis: results and side effects of 2 years of treatment.
D. N. Kolbach (1992)
10.1016/S0190-9622(82)70157-4
Combined methotrexate--ultraviolet B therapy in the treatment of psoriasis.
B. Paul (1982)
10.1046/j.1468-3083.2003.00519_12.x
Multiple cutaneous squamous carcinoma in a psoriatic associated with ciclosporin, alcohol abuse and ultraviolet radiation exposure which were suppressed by acitretin
K. Agnew (2003)
10.1111/j.1600-0625.1992.tb00071.x
A reappraisal of the use of 5‐methoxypsoralen in the therapy of psoriasis
P. Calzavara-Pinton (1992)
10.1001/ARCHDERM.1984.01650450051017
Psoralens and UV-A and UV-B twice weekly for the treatment of psoriasis.
K. M. Diette (1984)
10.1001/ARCHDERM.1971.04000130035004
Methotrexate for psoriasis. A new therapeutic schedule.
G. Weinstein (1971)
10.1159/000012336
A Pilot Study of Hypnosis in the Treatment of Patients with Psoriasis
F. Tausk (1999)
10.1111/j.1365-2133.1990.tb04192.x
Validation of Sickness Impact Profile and Psoriasis Disability Index in psoriasis
A. Finlay (1990)
Calcipotriol in combination with PUVA: a randomized double blind placebo study in severe psoriasis
A. Frappaz (1993)
Global safety and efficacy of up to five years of etanercept (Enbrel) therapy
L Klareskog (2001)
Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
A. Menter (2004)
10.1155/1996/213596
Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up.
D. Malatjalian (1996)
Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis.
A. Gottlieb (2004)
10.1111/j.1346-8138.1988.tb03652.x
Combination of Photochemotherapy (PUVA) and Ultraviolet B (UVB) in the Treatment of Psoriasis Vulgaris
Y. Park (1988)
10.1111/j.1610-0387.2005.05729.x
Cost‐of‐illness in patients with moderate and severe chronic psoriasis vulgaris in Germany
K. Berger (2005)
10.1016/S0140-6736(79)90820-1
COMPARISON OF PHOTOCHEMOTHERAPY AND DITHRANOL IN THE TREATMENT OF CHRONIC PLAQUE PSORIASIS
S. Rogers (1979)
10.1046/J.1365-2133.2001.04376.X
Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial.
S. Reitamo (2001)
10.1046/j.1365-2133.2002.04967.x
Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double‐blind, vehicle‐controlled clinical trial
L. Guenther (2002)
10.1159/000252574
Methotrexate for psoriasis in weekly oral doses without any adjunctive therapy.
A. Nyfors (1970)
10.1080/00015550310022916
Randomized half-side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis.
E. Snellman (2004)
10.1016/S0190-9622(82)70005-2
Combined methotrexate-PUVA therapy in the treatment of psoriasis.
W. Morison (1982)
10.1016/S0140-6736(88)91335-9
INTRALESIONAL INJECTION OF CYCLOSPORIN IN PSORIASIS
A. Powles (1988)
10.1016/J.MOLMED.2004.11.003
Dimethylfumarate for psoriasis: more than a dietary curiosity.
U. Mrowietz (2005)
10.1159/000057884
Safety and Efficacy of Combined High-Dose Treatment with Calcipotriol Ointment and Solution in Patients with Psoriasis
P. V. D. van de Kerkhof (2002)
10.1016/S0149-2918(98)80091-X
Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study.
J. Koo (1998)
10.1111/j.1365-2230.1978.tb01512.x
A randomized, controlled clinical trial comparing photochemotherapy with dithranol in the initial treatment of chronic plaque psoriasis
D. Vella Briffa (1978)
10.1067/MJD.2003.417
The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis.
T. S. Housman (2003)
10.1046/j.1365-2133.2003.05433.x
Long‐term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis
J. Hoefnagel (2003)
10.1016/S0190-9622(96)90025-0
Interruption of long-term methotrexate treatment in psoriasis: evaluation of clinical course and laboratory parameters after discontinuation and reintroduction of weekly oral methotrexate
E. Sherertz (1996)
Cyclosporine versus etretinate: Italian multicentre comparative trial in severe psoriasis
A F Finzi (1993)
10.1001/ARCHDERM.141.1.31
Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
A. Menter (2005)
10.1016/S0733-8635(18)30045-7
Tars and anthralins.
A. Silverman (1995)
10.1046/j.1365-2133.2001.04355.x
A comparison of the effect of narrow‐band ultraviolet B in the treatment of psoriasis after salt‐water baths and after 8‐methoxypsoralen baths
W. Arnold (2001)
10.1159/000248567
Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis.
J. Saurat (1988)
10.1080/09546630310019346
Fumaric acid esters in the treatment of psoriasis: an Italian experience
I. Carboni (2004)
10.1111/j.1346-8138.2002.tb00321.x
A Novel Liposomal Formulation of Dithranol for Psoriasis: Preliminary Results
R. Agarwal (2002)
10.1111/j.1365-2249.1994.tb06244.x
Elevated tumour necrosis factor‐alpha (TNF‐α) biological activity in psoriatic skin lesions
P. Ettehadi (1994)
10.1111/1523-1747.EP12506317
The effect of topical fluocinonide ointment on phototherapy of psoriasis.
M. Levine (1982)
10.2340/0001555577137141
Low-dose (1.25 mg/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile.
H. Meffert (1997)
10.5694/j.1326-5377.1990.tb125127.x
The treatment of psoriasis
H. Rotstein (1990)
10.1159/000063148
Topical Calcipotriol plus Oral Fumaric Acid Is More Effective and Faster Acting than Oral Fumaric Acid Monotherapy in the Treatment of Severe Chronic Plaque Psoriasis vulgaris
H. Gollnick (2002)
10.1159/000066440
A New Calcipotriol/Betamethasone Dipropionate Formulation (DaivobetTM) Is an Effective Once-Daily Treatment for Psoriasis vulgaris
R. Kaufmann (2002)
10.1159/000029933
Dithranol in a Cream Preparation: Disperse or Dissolve?
M. Prins (2000)
Nuclear factor of activated T cells (NFAT) as a molecular target for 1alpha,25-dihydroxyvitamin D3-mediated effects.
A. Takeuchi (1998)
10.1046/j.1365-2133.1998.02030.x
The effect of addition of calcipotriol ointment (50 μg/g) to acitretin therapy in psoriasis
Van De Kerkhof (1998)
Serum aminoterminal propeptide of type III procollagen. A non-invasive test for liver fibrogenesis in methotrexate-treated psoriatics.
H. Zachariae (1989)
10.1111/j.1365-2133.1995.tb02670.x
A comparison of twice‐weekly MPD‐PUVA and three times‐weekly skin typing‐PUVA regimens for the treatment of psoriasis
D. Buckley (1995)
10.1046/j.1365-4362.1999.00500.x
The role of salicylic acid in the treatment of psoriasis
M. Lebwohl (1999)
10.1177/039463200401700321
Association of Cyclosporine and 311 nM UVB in the Treatment of Moderate to Severe Forms of Psoriasis: A New Strategic Approach
C. Franchi (2004)
Systemic therapy of psoriasis using methotrexate.
K. Smith (2000)
Acitretin in the treatment of severe psoriasis: a randomized double-blind study comparing acitretin and etretinate.
H. Meffert (1989)
10.1007/s004030050251
Influence of monomethylfumarate on monocytic cytokine formation – explanation for adverse and therapeutic effects in psoriasis?
K. Asadullah (1997)
10.1067/MJD.2003.307
Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis.
A. Gottlieb (2003)
10.1046/j.1365-2133.1998.02124.x
Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study
Mrowietz (1998)
10.2340/00015555733740
Down-regulation of epidermal growth factor receptors by dithranol.
L. Kemény (1993)
10.1067/MJD.2002.120472
Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab.
R. Schopf (2002)
10.1046/j.1365-2133.2002.04698.x
Combining lesional short‐contact dithranol therapy of psoriasis with a potent topical corticosteroid
O. Swinkels (2002)
10.1046/j.1365-2133.1999.02766.x
Large increments in psoralen–ultraviolet A (PUVA) therapy are unsuitable for fair‐skinned individuals with psoriasis
Kirby (1999)
10.1046/j.1365-2133.2001.04074.x
Calcitriol 3 µg g−1 ointment in combination with ultraviolet B phototherapy for the treatment of plaque psoriasis: results of a comparative study
J. Ring (2001)
10.1007/S10227-002-0114-5
The Efficacy and Tolerability of Clobetasol Propionate Foam 0.05% in the Treatment of Mild to Moderate Plaque-type Psoriasis of Nonscalp Regions
A. Gottlieb (2003)
10.1159/000247323
Diflorasone diacetate ointment 0.05% versus betamethasone dipropionate ointment 0.05% in moderate-severe plaque-type psoriasis.
J. Shupack (1993)
Fotochemotherapie mit 8-Methoxypsoralen und UVA bei Psoriasis vulgaris
J Barth (1978)
The impact of the frequency of short contact dithranol treatment.
M. Prins (2001)
10.1111/J.1523-1747.2003.12605.X
Dimethylfumarate is a potent inducer of apoptosis in human T cells.
F. Treumer (2003)
10.1001/ARCHDERM.139.4.436
Efficacy of acitretin and commercial tanning bed therapy for psoriasis.
Christopher S Carlin (2003)
10.1111/j.1365-4362.1988.tb02429.x
Acitretin (Ro 10‐1670) in the Treatment of Severe Psoriasis
A. Ledo (1988)
10.1016/J.JACI.2004.03.021
Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis.
E. Schuller (2004)
10.1016/S0190-9622(99)80050-4
Failure to demonstrate therapeutic tachyphylaxis to topically applied steroids in patients with psoriasis.
J. Miller (1999)
10.1046/j.1365-2133.1998.02319.x
A randomized, double‐blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis
Koo (1998)
10.1111/j.1365-2133.1995.tb06924.x
Laser treatment of psoriasis
G. Katugampola (1995)
10.1007/S10227-001-0031-Z
A clinical evaluation of tazarotene 0.1% gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis
L. Green (2002)
The Hospital Anxiety and Depression Scale.
G. Huston (1987)
10.1016/S0190-9622(99)70008-3
A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis.
P. Gordon (1999)
Clobetasol propionate lotion in the treatment of moderate to severe plaque-type psoriasis.
J. Decroix (2004)
10.1046/j.1365-2133.1998.02400.x
The antipsoriatic agent dimethylfumarate immunomodulates T‐cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network
Ockenfels (1998)
10.1080/09546630305545
Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy
J. M. Camarasa (2003)
10.1046/j.1365-4362.2002.01431.x
A randomized, double‐blind, placebo‐controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis
M. Lebwohl (2002)
10.1046/j.1365-2133.1999.02974.x
A novel anti‐inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology
Grassberger (1999)
Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study.
Poulin Yp (1999)
10.1056/NEJM199101313240501
Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial.
C. Ellis (1991)
10.1016/S0190-9622(03)00792-8
Narrowband UVB and cream psoralen-UVA combination therapy for plaque-type psoriasis.
M. Grundmann-Kollmann (2004)
10.1016/S0140-6736(81)92137-1
ORAL 8-METHOXYPSORALEN PHOTOCHEMOTHERAPY OF PSORIASIS: The European PUVA Study: a Cooperative Study among 18 European Centres
T. Henseler (1981)
10.1016/S0190-9622(88)70086-9
Acitretin improves psoriasis in a dose-dependent fashion.
M. T. Goldfarb (1988)
[The practice guideline 'Photo(chemo)therapy and systemic therapy in severe chronic plaque-psoriasis'].
P. I. Spuls (2004)
10.1136/ARD.2004.032268
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
C. Antoni (2005)
Etanercept (Enbrel) monotherapy for more than 5 years in patients with DMARD-refrectory rheumatoid arthritis
L W Moreland (2002)
10.1159/000017504
Empfehlungen zur Erfassung von Lebensqualität in der Dermatologie
M. Augustin (2000)
10.1067/MJD.2000.108319
Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid.
M. Lebwohl (2000)
10.1002/ART.10172
Suppression of autoimmune arthritis in interleukin-1-deficient mice in which T cell activation is impaired due to low levels of CD40 ligand and OX40 expression on T cells.
S. Saijo (2002)
10.1016/S0190-9622(94)70121-0
Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients.
P. Altmeyer (1994)
10.1080/09546630310021947
A maintenance protocol for psoriasis plaques cleared by the 308 nm excimer laser
T. S. Housman (2004)
10.1016/0092-8674(91)90124-H
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
J. Liu (1991)
10.1159/000249793
Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics. A preliminary study.
A. Nyfors (1983)
Liver biopsy in methotrexate-treated psoriatics-a re-evalution.
H. Zachariae (1975)
10.1046/j.1365-2133.2003.05153.x
Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines
N. Litjens (2003)
10.1067/MJD.2000.107940
Tazarotene plus UVB phototherapy in the treatment of psoriasis.
J. Koo (2000)
10.1111/j.1468-3083.1997.tb00509.x
Dead sea bath salt for the treatment of psoriasis vulgaris: a double‐blind controlled study
S. Halevy (1997)
Ergebnisse einer Cyclosporin-behandlung bei schwerer, chronischer Psoriasis vulgaris
R Engst (1989)
10.1111/j.1365-2133.2003.05653.x
Optimizing the frequency of outpatient short‐contact dithranol treatment used in combination with broadband ultraviolet B for psoriasis: a randomized, within‐patient controlled trial
S. R. McBride (2003)
10.1067/MJD.2001.117850
The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody.
K. Papp (2001)
10.1177/247553030208A00301
Definitions of Measures of Effect Duration for Psoriasis Treatments
K. Gordon (2002)
10.1016/S0149-2918(97)80094-X
Mometasone furoate 0.1%-salicylic acid 5% ointment twice daily versus fluocinonide 0.05% ointment twice daily in the management of patients with psoriasis.
R. S. Medansky (1997)
10.1006/PHRS.1996.0069
Climatotherapy of psoriasis and hypertension in elderly patients at the Dead-Sea.
A. Kushelevsky (1996)
10.1016/S0190-9622(99)70362-2
Acitretin in combination with UVB or PUVA.
M. Lebwohl (1999)
10.1111/j.1365-2133.1996.tb07608.x
Efficacy and safety of topical calcitriol (1,25‐dihydroxyvitamin D3) for the treatment of psoriasis
A. Pérez (1996)
Oral retinoid and UVB radiation: a new, alternative treatment for psoriasis on an out-patient basis.
C. Orfanos (1979)
10.1016/S0091-6749(96)70163-X
Effects of cyclosporin A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells.
W. Sperr (1996)
10.1046/j.1365-2230.2000.00589.x
A comparison of bathwater and oral delivery of 8‐methoxypsoralen in PUVA therapy for plaque psoriasis
Cooper (2000)
10.1046/j.1365-2133.1996.35790.x
The value of dynamic hepatic scintigraphy and serum aminoterminal propeptide of type III procollagen for early detection of methotrexate‐induced hepatic damage in psoriasis patients
R. J. VANDOOREN‐GREEBE (1996)
10.1111/j.1365-2133.1994.tb02901.x
Methotrexate revisited: effects of long‐term treatment in psoriasis
R. J. Dooren-Greebe (1994)
10.1001/ARCHDERM.1982.01650170033018
The role of tar in Goeckerman therapy.
D. Belsito (1982)
Tuberculosis reports with etanercept (Enbrel) therapy
J Holman (2002)
Werfel T. Levels of circulating CD8+ T lymphocytes, natural killer cells, and eosinophils increase upon acute psychosocial stress in patients with atopic dermatitis
G Schmid-Ott (2001)
10.1046/j.1365-2133.2002.04622.x
A cognitive‐behavioural symptom management programme as an adjunct in psoriasis therapy
D. Fortune (2002)
10.1046/j.1365-2133.2000.04713.x
Topical preparations for the treatment of psoriasis: a systematic review
J. Mason (2002)
10.1016/0190-9622(91)70091-F
A 12-month treatment of severe psoriasis with acitretin: results of a Canadian open multicenter study.
H. Murray (1991)
10.1046/j.1365-2133.1998.02554.x
The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion
Mrowietz (1998)
10.1001/ARCHDERM.139.3.325
Narrowband UV-B (TL-01) phototherapy vs oral 8-methoxypsoralen psoralen-UV-A for the treatment of chronic plaque psoriasis.
T. Markham (2003)
10.2340/0001555576353356
Topical treatment by urea reduces epidermal hyperproliferation and induces differentiation in psoriasis.
I. Hagemann (1996)
10.1001/ARCHDERM.1979.04010090024017
Combination therapy for psoriasis. Psoralens plus long-wave ultraviolet radiation with betamethasone valerate.
C. Hanke (1979)
10.1159/000057974
Atopic Eczema Prevention Program in Childhood and Adolescence – a Model Project of the GermanGovernment
G. Schmid-Ott (2000)
10.1111/j.1365-2133.2005.06422.x
Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long‐term methotrexate: a multicentre audit and health economic analysis
R. Chalmers (2005)
10.1016/S0011-393X(05)80413-8
A comparative study of mometasone furoate ointment and betamethasone valerate ointment in patients with psoriasis vulgaris
Å. Svensson (1992)
Efalizumab for mour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions
K B Gordon (1994)
10.1001/ARCHDERM.141.1.43
Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment.
C. Carroll (2005)
10.1111/j.1365-2133.1992.tb00458.x
Inhibition of human monocyte functions by anthralin
U. Mrowietz (1992)
10.1111/j.1365-2133.1992.tb00460.x
Bath-water compared with oral delivery of 8-methoxypsoralen PUVA therapy for chronic plaque psoriasis.
P. Collins (1992)
The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis.
P. V. D. van de Kerkhof (1998)
10.1067/MJD.2001.113448
Liver biopsies and methotrexate: a time for reconsideration?
R. Chalmers (2001)
Randomized double-blind multicenter study comparing acitretin-PUVA and placebo-PUVA in the treatment of severe psoriasis
J H Saurat (1988)
10.1046/j.1365-2133.1999.02976.x
Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis
Clark (1999)
10.1111/1523-1747.EP12319272
Commercial tanning bed treatment is an effective psoriasis treatment: results from an uncontrolled clinical trial.
A. Fleischer (1997)
10.1016/S0190-9622(98)70214-2
Narrow band UVB (311 nm) phototherapy and PUVA photochemotherapy: a combination.
P. Calzavara-Pinton (1998)
10.1016/S0190-9622(88)70198-X
Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study.
H. Gollnick (1988)
10.1111/j.1365-2133.1984.tb07470.x
A randomized double‐blind comparison of PUVA‐etretinate and PUVA‐placebo in the treatment of chronic plaque psoriasis
S. Parker (1984)
10.1111/j.1365-4362.1992.tb02669.x
LIVER BIOPSY VERSUS ULTRASOUND IN METHOTREXATE‐TREATED PSORIASIS: A DECISION ANALYSIS
ARNAUD C. Verschuur (1992)
10.1067/MJD.2001.112400
Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study.
V. Ho (2001)
10.1007/s001050050401
Das Wirkungs- und Sicherheitsprofil von Fumarsäureestern in der oralen Langzeittherapie bei schwerer therapieresistenter Psoriasis vulgaris Eine Untersuchung an 83 Patienten
P. Altmeyer (1996)
10.1111/j.1365-2133.1989.tb01406.x
A double‐blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis
J. Lauharanta (1989)
10.1007/BF01105083
Cyclosporin A, FK506 and dithranol alter tyrosine-specific protein phosphorylation in HaCaT keratinocytes
H. M. Ockenfels (2005)
10.1001/ARCHDERM.1992.01680160143028
The effect of flash lamp-pulsed dye laser on psoriasis.
S. M. Hacker (1992)
10.1016/S0190-9622(98)70508-0
Methotrexate in psoriasis: consensus conference.
H. Roenigk (1998)
Efficacy and safety of oral cyclosporine A (CYA; Sandimmun) for longterm treatment of chronic severe plaque psoriasis
C Laburte (1994)
Perorale Langzeitbehandlung der Psoriasis mit Fumarsäurederivaten
W Bayard (1987)
10.1111/j.1365-2230.1992.tb02161.x
The efficacy of methotrexate in psoriasis—a review of 40 cases
P. Collins (1992)
10.1046/j.1365-4362.2000.00913.x
Psoralen–ultraviolet A therapy vs. psoralen–ultraviolet B therapy in the treatment of plaque‐type psoriasis: our experience with Fitzpatrick skin type IV
K. Khurshid (2000)
10.1001/ARCHDERM.134.9.1101
Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study.
I. Zonneveld (1998)
10.1111/j.1365-2133.1988.tb03224.x
Aminoterminal propeptide of type III procollagen in methotrexate‐induced liver fibrosis and cirrhosis
J. Risteli (1988)
10.1056/NEJMOA030409
Etanercept as monotherapy in patients with psoriasis.
C. Leonardi (2003)
10.1200/JCO.1996.14.10.2769
Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors.
G. Rustin (1996)
10.1046/j.1365-2249.2003.02225.x
Pimecrolimus does not affect the differentiation, maturation and function of human monocyte‐derived dendritic cells, in contrast to corticosteroids
F. Kalthoff (2003)
10.1080/09546630410023322
A combination therapy of calcipotriol cream and PUVA reduces the UVA dose and improves the response of psoriasis vulgaris
H. Torras (2004)
Fachinformation, essex pharma; aktuelle Version
Methotrexate for psoriasis in weekly oral JDDG | Supplement 2˙2006 (Band 4) doses without any adjunctive therapy
H Nyfors A Und Brodthagen (1970)
10.1016/0163-8343(89)90036-4
A psychocutaneous profile of psoriasis patients who are stress reactors. A study of 127 patients.
M. Gupta (1989)
10.1159/000018457
The Efficacy, Safety and Tolerance of Calcitriol 3 μg/g Ointment in the Treatment of Plaque Psoriasis: A Comparison with Short-Contact Dithranol
P. E. Hutchinson (2000)
10.1067/MJD.2003.130
Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis.
K. Papp (2003)
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.
L. Moreland (1999)
10.1046/J.1439-0353.2003.03615.X
Recommendations for phototherapy and photochemotherapy
E. Hölzle (2003)
10.1097/00000441-195102000-00009
THERAPEUTIC SUPPRESSION OF TISSUE REACTIVITY: II. Effect of Aminopterin in Rheumatoid Arthritis and Psoriasis
R. Gubner (1951)
10.1046/J.1523-1747.2003.12040.X
Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study.
C. Paul (2003)
10.1016/J.JAAD.2004.02.021
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.
A. Gottlieb (2004)
10.1046/j.1365-2133.1999.02927.x
Tacrolimus ointment improves psoriasis in a microplaque assay
Remitz (1999)
10.1159/000210784
The relevance of salicylic acid in the treatment of plaque psoriasis with dithranol creams.
S. de Mare (1988)
10.4049/jimmunol.167.9.4974
1α,25-Dihydroxyvitamin D3 Has a Direct Effect on Naive CD4+ T Cells to Enhance the Development of Th2 Cells1
A. Boonstra (2001)
10.1016/0190-9622(95)90189-2
Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement.
G. Mahrle (1995)
10.1006/BBRC.1997.6570
Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells.
M. Vandermeeren (1997)
10.1067/MJD.2002.125075
Medium-dose 308-nm excimer laser for the treatment of psoriasis.
M. Trehan (2002)
[Peroral long-term treatment of psoriasis using fumaric acid derivatives].
W. Bayard (1987)
10.1111/j.1365-2133.1989.tb01402.x
Relapse rates in moderately severe chronic psoriasis treated with cyclosporin A
E. Higgins (1989)
10.1056/NEJMOA030002
A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.
M. Lebwohl (2003)
10.1016/S0190-9622(89)70138-9
Side-effect profile of acitretin therapy in psoriasis.
A. Gupta (1989)
10.1016/0190-9622(91)70089-K
Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone.
N. Lowe (1991)
10.1046/j.1365-2133.2000.03883.x
Acitretin is converted to etretinate only during concomitant alcohol intake
F. Grønhøj Larsen (2000)
Comparison of two therapeutic regimens, continuous monotherapy and intermittent therapy, for long-term maintenance of remission of psoriasis with cyclosporin A
J. Nakayama (1996)
10.1016/s0190-9622(96)80148-4
Proceedings of the Psoriasis Combination and Rotation Therapy Conference
Jo-Ann See Mb Facd (1996)
A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group.
J. Koo (1998)
Cyclosporine for plaquetype psoriasis. Results of a multidose, double-blind trial
C N Ellis (1991)
10.1067/MAI.2001.111850
Levels of circulating CD8(+) T lymphocytes, natural killer cells, and eosinophils increase upon acute psychosocial stress in patients with atopic dermatitis.
G. Schmid-Ott (2001)
10.3109/09546639109086777
Clinical efficacy and safety of augmented betamethasone dipropionate ointment and diflorasone diacetate ointment for psoriasis - a multicentre, randomized, double-blinded study
Tsu‐Yi Chuang (1991)
10.1111/j.1365-2133.2005.06306.x
Safety and efficacy study on etanercept in patients with plaque psoriasis
A. Costanzo (2005)
10.1016/J.JAAD.2004.09.029
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.
C. Leonardi (2005)
Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis.
A. Mussi (1997)
10.1001/ARCHDERM.1997.03890480034005
Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B.
T. Coven (1997)
10.1111/j.0007-0963.2004.05739.x
Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities
P. Balasubramaniam (2004)
10.1016/S0926-9959(97)00181-5
Calcipotriol improves the efficacy of cyclosporine in the treatment of psoriasis vulgaris.
F. Kokelj (1998)
10.1016/0190-9622(93)70069-6
Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis.
P. Duhra (1993)
10.1111/j.1365-2133.1992.tb00126.x
A multicentre, parallel‐group comparison of calcipotriol ointment and short‐contact dithranol therapy in chronic plaque psoriasis
J. Berth-Jones (1992)
10.1016/S0190-9622(84)70188-5
Role of ultraviolet A in phototherapy for psoriasis.
K. M. Diette (1984)
10.1001/JAMA.290.23.3073
Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
K. Gordon (2003)
10.1159/000066425
Body-Weight-Independent Dosing of Cyclosporine Micro-Emulsion and Three Times Weekly Maintenance Regimen in Severe Psoriasis
D. Thąci (2002)
10.1097/00006842-199809000-00020
Influence of a Mindfulness Meditation-Based Stress Reduction Intervention on Rates of Skin Clearing in Patients With Moderate to Severe Psoriasis Undergoing Photo Therapy (UVB) and Photochemotherapy (PUVA)
J. Kabat-Zinn (1998)
10.1080/00015550310003791
Papular neutrophilic dermatosis and erythema elevatum diutinum following erythropoietin therapy in a patient with myelodysplastic syndrome.
E. Gubinelli (2003)
10.1111/1523-1747.EP12274997
Multifunctional inhibition by anthralin in nonstimulated and chemotactic factor stimulated human neutrophils.
J. Schröder (1985)
10.2340/0001555574295297
The systemic effect of dithranol treatment in psoriasis.
M. Goodfield (1994)



This paper is referenced by
Therapieziele bei Patienten mit Psoriasis und Ulcus cruris : Ausprägung und Einflussfaktoren
Ramona Gosau (2012)
10.1055/S-0030-1256636
Psoriasis verursacht hohe Kosten, mindert die Produktivität am Arbeitsplatz und verringert die Lebensqualität
M. Augustin (2011)
10.1080/09546634.2020.1720580
Correct performance of subcutaneous injections in plaque psoriasis: comparison of trained and untrained patients with different application systems in routine clinical care.
Franziska Stenger (2020)
10.1111/j.1610-0387.2012.07893.x
Processes of psoriasis health care in Germany – long‐term analysis of data from the statutory health insurances
M. Augustin (2012)
Treatment goals in psoriasis
e. g. Lantarel ()
10.1111/ddg.12059
Efficacy and safety of fumaric acid esters in patients with psoriasis on medication for comorbid conditions – a retrospective evaluation (FACTS)
D. Thąci (2013)
10.1007/s00105-008-1662-4
Behandlungsstrategien bei Psoriasis vulgaris und Psoriasisarthritis
Gottfried Wozel (2008)
10.1055/S-0043-111706
Rehabilitation von Kindern und Jugendlichen mit chronischen Hauterkrankungen
Rainer Stachow (2017)
10.1016/S0140-6736(07)61129-5
Current and future management of psoriasis
A. Menter (2007)
10.1007/s00105-020-04607-1
Psoriasis und Schwangerschaft
B. Stephan (2020)
10.1111/jdv.12355
Social problem‐solving, perceived stress, negative life events, depression and life satisfaction in psoriasis
M. Eskin (2014)
10.1111/ddg.12381
Occupational palmoplantar psoriasis: a clinical case series with consideration of the S1 guidelines on expert medical assessments of occupational psoriasis
Irena Angelovska (2014)
10.1016/j.jaad.2004.10.735
Efalizumab in the treatment of psoriasis
W. Boehncke (2007)
10.1111/jdv.13783
Methods report on the development of the European evidence‐based (S3) guideline for the treatment of acne – update 2016
A. Nast (2016)
10.1007/s00105-017-4105-2
308 nm-Excimerlaser zur Therapie von Psoriasis und entzündlichen Hauterkrankungen
Karsten Fritz (2017)
10.1111/j.1365-2230.2012.04351.x
Fumaric acid esters as a suitable first‐line treatment for severe psoriasis: an Irish experience
K. Heelan (2012)
10.1111/ddg.12198
Dear‐Doctor‐Letter Fumaderm® – What are the facts?
U. Mrowietz (2013)
German S3-guidelines on the treatment of psoriasis vulgaris (short version) A. NastW. H. BoehnckeU. MrowietzH. M. OckenfelsS. PhilippK. ReichT. Rosenbach • A. SammainM. SchlaegerM. SebastianW. SterryV. StreitM. AugustinR. ErdmannJ. Klaus •
J. KozaS (2012)
10.1007/s00105-011-2296-5
Zehn Jahre Biologics in der Dermatologie
Gottfried Wozel (2011)
10.1007/978-3-642-39940-4_19
Hautkrankheiten des Penis
Walter Krause (2016)
10.1111/ddg.12396_suppl
Topische Langzeittherapie der Psoriasis mit Vitamin‐D3‐Analoga, Kortikosteroiden und deren Kombinationen: Positionspapier zu Evidenz und praktischer Anwendung
M. Augustin (2014)
10.1007/s00403-009-0978-y
Do guidelines change the way we treat? Studying prescription behaviour among private practitioners before and after the publication of the German Psoriasis Guidelines
A. Nast (2009)
10.1007/978-3-319-66884-0_20
Fumaric Acid Esters in Dermatology
Katrina Lee (2018)
10.1007/s00403-016-1651-x
Quality of psoriasis care in Germany: results of the national health care study “PsoHealth3”
A. Langenbruch (2016)
10.1111/jdv.14811
Guideline‐compliant prescription of biologicals and possible barriers in dermatological practices in Bavaria
M. Schielein (2018)
10.1111/j.1610-0387.2007.06240.x
Costs and quality of life in patients with moderate to severe plaque‐type psoriasis in Germany: A multi‐center study
O. Schöffski (2007)
10.1038/jid.2012.124
Why statistics matter: limited inter-rater agreement prevents using the psoriasis area and severity index as a unique determinant of therapeutic decision in psoriasis.
Pierre-Antoine Gourraud (2012)
10.1007/s13555-020-00376-w
Evaluation of Accountability Measurement Tool in Patients with Psoriasis: A Validation Study
Jennifer J Su (2020)
Psoriasis 2 Current and future management of psoriasis
A. Menter (2007)
10.1111/j.1610-0387.2008.06807.x
Quality of psoriasis care in Germany – results of the national study PsoHealth 2007
M. Augustin (2008)
10.1055/S-0043-104762
Psychodermatologie und geschlechtsspezifische Aspekte chronischer Hauterkrankungen
Gerhard Schmid-Ott (2017)
10.1159/000320111
Cost-Effectiveness of Biological Therapy in Remission Induction of Moderate to Severe Plaque Psoriasis
K. Schmitt-Rau (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar